NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NDA FilingPrimeCPositive

AI Analysis

Summary

NeuroSense secured a Nasdaq hearing date and maintains compliance with minimum bid price requirements. The company expects to submit a New Drug Submission to Health Canada in December 2026 and anticipates a decision on non-dilutive funding for the Phase 3 PARAGON trial in Q1 2027.

Clinical Trial Data

Phase

Outcome Details

New Drug Submission to Health Canada targeted for December 2026

Importance:6/10

Sentiment:

0.40

regulatoryNasdaqHealth CanadaPhase 3fundingNDA Filing

Related Companies

$NRSNW

Read the original article

Published by PR Newswire Pharma on October 13, 2026 12:30 PM

Read Original